Skip to Content

Novavax, Inc.

Securities Class Action

  • Date:
  • 1/11/2022
  • Company Name:
  • Novavax, Inc.
  • Stock Symbol:
  • NVAX
  • Class Period:
  • FROM 3/2/2021 TO 10/19/2021
  • Status:
  • Filed
  • Court:
  • U.S. District Court: District of Maryland

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) in the United States District Court for the Southern District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Novavax securities between March 2, 2021 and October 19, 2021, both dates inclusive (the “Class Period”). Investors have until January 11, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373, a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 coronavirus; (ii) as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization regulatory timelines for NVX-CoV2373; (iii) accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
 

If you purchased or otherwise acquired Novavax shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by filling out the contact form below. There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Novavax. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: